Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Baxter agreed to acquire Hillrom for $156 per share in cash, with a total enterprise value of approximately $12.4 billion including assumed debt.
Baxter International finalized its $10.5 billion acquisition of Hillrom Holdings, combining two major medical device manufacturers in a significant industry…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Baxter International acquired Hillrom for $156 per share in cash for total equity value of approximately $10.5 billion and enterprise value of approximately $12.4 billion. The deal expanded Baxter's digital health and connected care offerings.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Baxter International Inc. / Hillrom Holdings Inc. (this deal) | 2021 | $12.4B | 48 |
| Baxter International Inc. / ESI Lederle (Wyeth generic injectable business) | 2002 | $316M | 33 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |